## **AMENDMENT**

## In the Specification:

Please replace the first paragraph at lines 4-9 of page 1 with:

--This application is a divisional application of U.S. Application Serial No. 09/316,761 filed 21 May 1999, and now pending which is a continuation-in-part of U.S. Application Serial No. 09/275,176, filed 24 March 1999, now U.S. patent 6,340,685,, which is a continuation-in-part of U.S. Serial No. 09/128,137, filed 3 August 1998 and now U.S. patent 6,130,235, which application claims priority under 35 U.S.C. § 119(e) of provisional application 60/086,531 filed 22 May 1998. The contents of these applications are incorporated herein by reference.--

Please amend the claims as follows:

## In the Claims:

===

L,

Please cancel claims 1-38 and replace them with the following claims:

39. (New) A compound of the formula:

$$R^{3}$$
 $Z^{1}$ 
 $Z^{2}$ 
 $Z^{2}$ 
 $Z^{2}$ 
 $Z^{2}$ 

 $Z^1$   $(\beta)$   $R^2$ 

and the pharmaceutically acceptable salts thereof,

wherein each of  $Z^1$  and  $Z^2$  is independently  $CR^4$  or N;

where each R<sup>4</sup> is independently selected from the group consisting of H, alkyl (1-6C) and aryl, each of said alkyl and aryl optionally including one or more heteroatoms selected from O, S, and N and each of said alkyl being optionally substituted by one or more substituents selected from the group consisting of halo, OR, SR, NR<sub>2</sub>, RCO/COOR, CONR<sub>2</sub>, OOCR, NROCR, CN, =O, a five- or six-membered saturated carbocyclic ring or heterocyclic ring containing 1-2 N, and a six-membered aromatic ring optionally containing 1-2 N, where R in the foregoing

or

Serial No.: Not yet assigned. Docket No. 219002028310

sd-77130